Table 8.
Health outcomes per 1,000 for each prophylaxis strategy–eTHR population.
| Intervention Short-term health outcomes (n [95% CI]) | Long-term health outcomes (n [95% CI]) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Symptomatic DVTs | Sympt proximal DVT | Asymptomatic DVTs | PEs | Total VTEs | Surgical site bleeding | Total deaths | PTS | CTEPH | |
| LMWH (std,std) + AES | 9 (8 to 11) |
8 (6 to 9) |
46 (44 to 48) |
7 (6 to 7) |
62 (61 to 64) |
28 (7 to 83) |
1 (1 to 3) |
7 (6 to 8) |
0 (0 to 0) |
| LMWH (std,extd)+ AES | 6 (1 to 19) |
5 (1 to 16) |
27 (4 to 96) |
1 (0 to 9) |
34 (5 to 116) |
29 (2 to 131) |
0 (0 to 2) |
4 (1 to 13) |
0 (0 to 0) |
| Fondaparinux+ AES | 20 (7 to 42) |
17 (6 to 35) |
98 (36 to 204) |
12 (1 to 52) |
130 (52 to 263) |
51 (8 to 187) |
2 (0 to 11) |
14 (6 to 30) |
0 (0 to 2) |
| Foot pump + AES | 25 (3 to 81) |
21 (3 to 68) |
122 (16 to 388) |
22 (3 to 87) |
169 (35 to 486) |
13 (2 to 49) |
5 (0 to 19) |
19 (4 to 54) |
1 (0 to 3) |
| IPCD | 56 (10 to 134) |
47 (8 to 111) |
275 (49 to 634) |
53 (2 to 299) |
383 (79 to 858) |
13 (2 to 49) |
11 (0 to 62) |
43 (9 to 99) |
b (0 to 9) |
| AES (above knee) | 16 (2 to 58) |
14 (1 to 48) |
80 (8 to 278) |
106 (0 to 909) |
203 (16 to 996) |
13 (2 to 49) |
23 (0 to 202) |
26 (2 to 138) |
3 (0 to 26) |
| Foot pump | 17 (1 to 73) |
14 (1 to 61) |
84 (5 to 363) |
213 (1 to 980) |
314 (20 to 1078) |
13 (2 to 49) |
44 (0 to 243) |
41 (2 to 152) |
6 (0 to 30) |
| AES | 20 (1 to 91) |
16 (1 to 76) |
97 (4 to 440) |
11 (1 to 49) |
127 (11 to 539) |
13 (2 to 49) |
2 (0 to 11) |
14 (1 to 58) |
0 (0 to 2) |
| LMWH (std,std) | 34 (6 to 93) |
28 (5 to 78) |
168 (29 to 451) |
25 (2 to 128) |
227 (48 to 573) |
28 (7 to 83) |
5 (0 to 27) |
26 (6 to 65) |
1 (0 to 4) |
| LMWH (std,extd) | 32 (3 to 100) |
27 (3 to 83) |
158 (17 to 482) |
4 (0 to 32) |
194 (22 to 589) |
29 (2 to 131) |
1 (0 to 6) |
21 (2 to 65) |
0 (0 to 1) |
| Aspirin (std duration) | 10 (2 to 32) |
8 (1 to 26) |
49 (8 to 156) |
373 (3 to 995) |
433 (34 to 1066) |
10 (8 to 12) |
79 (1 to 288) |
60 (4 to 155) |
11 (0 to 31) |
| LMWH (std, std) + Aspirin | 1 (0 to 8) |
1 (0 to 7) |
6 (0 to 42) |
1 (0 to 6) |
8 (0 to 55) |
22 (0 to 190) |
0 (0 to 1) |
1 (0 to 6) |
0 (0 to 0) |
| Dabigatran | 48 (4 to 136) |
40 (4 to 113) |
233 (21 to 649) |
37 (1 to 204) |
317 (42 to 830) |
44 (6 to 160) |
8 (0 to 43) |
36 (5 to 93) |
1 (0 to 6) |
| Apixaban | 7 (0 to 30) |
6 (0 to 26) |
33 (2 to 145) |
21 (0 to 131) |
61 (6 to 252) |
42 (4 to 173) |
4 (0 to 28) |
7 (1 to 32) |
1 (0 to 4) |
| Rivaroxaban | 35 (4 to 110) |
29 (3 to 92) |
171 (19 to 527) |
13 (0 to 88) |
219 (28 to 651) |
36 (4 to 138) |
3 (0 to 18) |
24 (3 to 73) |
0 (0 to 3) |
| No prophylaxis | 68 (16 to 139) |
57 (13 to 115) |
335 (80 to 669) |
88 (8 to 384) |
491 (146 to 953) |
13 (2 to 49) |
18 (1 to 82) |
56 (16 to 112) |
3 (0 to 12) |
a AES, anti-embolism stockings; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; eTHR, elective total hip replacement; extd, extended; IPCD, intermittent pneumatic compression devices; LMWH, low molecular weight heparin; PE, pulmonary embolism; PTS, post thrombotic syndrome; std, standard; VTE, venous thromboembolism.